Progressive Familial Intrahepatic Cholestasis in Indian Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-28

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The project will amalgamate data from several large Indian centers to describe the genotype, clinical spectrum, natural course, genotype-phenotype correlation, outcome, and response to medical therapy in Indian children with progressive familial intrahepatic cholestasis (PFIC). This will be the first such Indian registry of children with PFIC. There are currently limited single-center studies describing the genotype, natural course, and outcome of Indian children with PFIC.

Data will be collected retrospectively from the participating centers across the country. Only genetically confirmed cases would be included.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)

NCT00571272

Liver Diseases Alagille Syndrome Alpha 1-Antitrypsin Deficiency

SUSPENDED

Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease

NCT05582447

Cholestasis Red Cell Membrane and Enzyme Abnormalities

ACTIVE_NOT_RECRUITING

Paternally Inherited Phenotypes in Cholestasis

NCT03337074

Cholestasis Primary Sclerosing Cholangitis Primary Biliary Cirrhosis

UNKNOWN

Nutritional Assessment Tool in Childhood Chronic Liver Disease

NCT02802761

Chronic Liver Disease

COMPLETED

Nutritional Assessment Tool and Nutritional Intervention in Childhood Chronic Liver Disease

NCT02715973

Chronic Liver Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is a lack of robust literature from India on PFIC. The study would be the first to extensively describe the genotype of Indian children with PFIC and their natural course. Being a multicentric study, the results generated would therefore be applicable to the whole of the country. Understanding the prevalent genotypes in the Indian population and their related phenotype would help both the individual management decisions of these patients and further policy-making for their diagnosis and treatment. With the advent of genetic diagnosis through sequencing techniques and these tests becoming more affordable, every Indian center is now diagnosing a fair number of these cases which used to go undiagnosed previously. This has changed the landscape of cholestatic liver disease in children where PFICs are now the most prevalent pediatric cholestatic disorder. European studies have demonstrated 2 common mutations where patients respond very well to surgical biliary diversion and have good native liver survival. These mutations have rarely been reported in India. Results from this study could thus guide appropriate decision-making based on outcome and help choose the modality of treatment for the individual patient - medical, surgical biliary diversion, or liver transplantation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Progressive Familial Intrahepatic Cholestasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Genetically proven homozygous or compound heterozygous mutations of ATP8B1/ ABCB11/ ABCB4/ TJP2/ NR1H4/ MYO5B/ USP53/ KIF12 AND
* Clinical and biochemical evidence of chronic cholestatic disease AND / OR
* Histological features of intrahepatic cholestasis with suggestive immunohistochemistry

Exclusion Criteria

* Genetic analysis showing mutations unrelated to intrahepatic cholestasis according to database
* Clinical, biochemical, and histological evidence of progressive familial intrahepatic cholestasis without a genetic sequencing report

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No